Litton Mark James — SEC Form 4 filings
SEC reporting owner CIK 1604834. 12 Form 4 filings on record with FilingPulse; latest filed 2026-04-13.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-16 to 2026-04-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 6 filings — 67,824 shares, $83,835 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 5,156 shares @ $5.37 ($27,688) in LeonaBio, Inc., filed 2026-03-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | PRESIDENT and CEO, Director | 12 | — | 6 legs · 67,824 sh · $83,835 | 18 |
Form 4 filings — Litton Mark James
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-13 | 4 | LeonaBio, Inc. (LONA) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | LeonaBio, Inc. (LONA) | Option exercise (M): 22,254 @ $0 · Sale (S): 5,156 @ $5.37 · Option exercise (M): 22,254 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Athira Pharma, Inc. (ATHA) | Option exercise (M): 10,834 @ $0 · Sale (S): 2,586 @ $6.88 · Option exercise (M): 10,834 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 133,526 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Athira Pharma, Inc. (ATHA) | Option exercise (M): 108,334 @ $0 · Sale (S): 25,123 @ $0.29 · Option exercise (M): 108,334 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 333,815 (derivative) @ $0 · Grant/award (A): 222,543 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Athira Pharma, Inc. (ATHA) | Option exercise (M): 108,333 @ $0 · Sale (S): 25,107 @ $0.56 · Option exercise (M): 108,333 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4/A | Athira Pharma, Inc. (ATHA) | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 325,000 (derivative) @ $0 · Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 20,000 @ $0 · Sale (S): 5,032 @ $0.57 | EDGAR |
| 2024-02-16 | 4/A | Athira Pharma, Inc. (ATHA) | Grant/award (A): 20,000 @ $0 · Sale (S): 4,820 @ $2.91 | EDGAR |
| 2024-02-16 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1604834 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →